CareDx found to have not infringed on one Natera patent, infringed on another

CareDx (CDNA) announced the jury verdict in the patent litigation brought by Natera (NTRA). CareDx was found to have not infringed on Natera patent 10,655,180 and found to have infringed on Natera patent 11,111,544. During pre-trial motions, the Court dismissed an additional patent asserted by Natera against CareDx. The District of Delaware jury awarded Natera damages including lost profits of $83,679,521 and past royalty of $12,535,500 for alleged infringement by AlloSure, occurring from September 2021 through August 2023. CareDx intends to seek judicial review of the verdict. The decision does not affect access and availability to CareDx’s current offerings, including AlloSure or AlloMap. There is no motion pending for injunctive relief.